Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Taiwan Advance Bio-Pharmaceutical's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,033.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$22.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical EV-to-EBIT Related Terms
Taiwan Advance Bio-Pharmaceutical EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4186 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT falls into.
Taiwan Advance Bio-Pharmaceutical's current Enterprise Value is NT$771.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$22.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a EV-to-EBIT of 35.04 as of Sep. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #274 out of 368 companies in the Biotechnology industry, placing it in the top 74.5%.
Is Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT too high?
Taiwan Advance Bio-Pharmaceutical's current EV-to-EBIT is 35.04. The Biotechnology industry median EV-to-EBIT is 15.50. Taiwan Advance Bio-Pharmaceutical's value of 35.04 is 126.1% above this industry median. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #274 out of 368 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #274 out of 368 companies for EV-to-EBIT. This places Taiwan Advance Bio-Pharmaceutical in the lower half of its industry. The industry median EV-to-EBIT is 15.50. Taiwan Advance Bio-Pharmaceutical's value of 35.04 is 126.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.50, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advance Bio-Pharmaceutical's current EV-to-EBIT of 35.04 is 126.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current EV-to-EBIT is 35.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$15.94, compared to a current price of NT$7.00 — trading 56.1% below its estimated fair value. The current EV-to-EBIT is 35.04 and 126.1% above the Biotechnology industry median of 15.50. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current EV-to-EBIT is 35.04 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$7.00 is trading 56.1% below its estimated GF Value™ of NT$15.94.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
EV-to-EBIT: 35.04
GF Value™: NT$15.94 vs. price of NT$7.00 (56.1% below fair value)
Industry Position: 126.1% above the Biotechnology median (#274 of 368)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
57GF Score
Get the complete analysis for ROCO:4186
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
